fda3da0a-ae39-53a2-a7d6-d4f5f15dcc67

New drug approach offers hope for patients with recurrent aggressive cancers

Merck announces that sac-TMT, a new cancer drug, demonstrated strong results in phase 3 trials for advanced or recurrent endometrial cancer patients.